Conversely, in pCCA subtype, it has been shown that Sprouty RTK signaling antagonist 4 (SPRY4) is significantly downregulated in tumor tissue compared to adjacent non-tumor tissue, and that its low expression correlates with worse prognosis [72]. The gene discussed is SPRY4; the disease is neoplasm.